• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email
    SC 13D/A 1 d783044dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

     

    Cronos Group Inc.

    (Name of Issuer)

    Common Shares, no par value

    (Title of Class of Securities)

    22717L101

    (CUSIP Number)

    W. Hildebrandt Surgner, Jr.

    Vice President, Corporate Secretary and

    Associate General Counsel

    Altria Group, Inc.

    6601 West Broad Street

    Richmond, Virginia 23230

    (804) 274-2200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    Copy to:

    Andrew J. Nussbaum, Esq.

    John L. Robinson, Esq.

    Wachtell, Lipton, Rosen & Katz

    51 West 52nd Street

    New York, New York 10019

    (212) 403-1000

    April 25, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 22717L101

     

     1   

     NAME OF REPORTING PERSON

     

     Altria Group, Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☒  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC, OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Virginia

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     - 0 -

        8   

     SHARED VOTING POWER

     

     156,573,537 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     - 0 -

       10   

     SHARED DISPOSITIVE POWER

     

     156,573,537 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     156,573,537 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     41.0% (2)

    14  

     TYPE OF REPORTING PERSON

     

     HC and CO

     

    (1)

    The amount reported represents 156,573,537 common shares, no par value (the “Common Shares”), of Cronos Group Inc. (“Cronos” or the “Issuer”) directly held by Maple Acquireco (Canada) ULC (“Canada Acquireco”) and beneficially owned by Altria Group, Inc. (“Altria”) with respect to which Altria has shared dispositive power and voting power. Canada Acquireco is a wholly owned subsidiary of Altria.

    (2)

    Based on a total of 382,011,178 Common Shares issued and outstanding as of March 31, 2024, based on information provided by the Issuer.


    CUSIP No. 22717L101

     

     1   

     NAME OF REPORTING PERSON

     

     Altria Summit LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☒  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Virginia

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     - 0 -

        8   

     SHARED VOTING POWER

     

     156,573,537 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     - 0 -

       10   

     SHARED DISPOSITIVE POWER

     

     156,573,537 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     156,573,537 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     41.0% (2)

    14  

     TYPE OF REPORTING PERSON

     

     OO (limited liability company)

     

    (1)

    The amount reported represents 156,573,537 Common Shares directly held by Canada Acquireco and beneficially owned by Altria Summit LLC (“Altria Summit”) with respect to which Altria Summit has shared dispositive power and voting power.

    (2)

    Based on a total of 382,011,178 Common Shares issued and outstanding as of March 31, 2024, based on information provided by the Issuer.


    CUSIP No. 22717L101

     

     1   

     NAME OF REPORTING PERSON

     

     Maple Holdco (Bermuda) Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☒  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Virginia

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     - 0 -

        8   

     SHARED VOTING POWER

     

     156,573,537 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     - 0 -

       10   

     SHARED DISPOSITIVE POWER

     

     156,573,537 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     156,573,537 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     41.0% (2)

    14  

     TYPE OF REPORTING PERSON

     

     OO (limited company)

     

    (1)

    The amount reported represents 156,573,537 Common Shares directly and beneficially owned by Canada Acquireco and beneficially owned by Maple Holdco (Bermuda) Ltd. (“Bermuda Holdco”) with respect to which Bermuda Holdco has shared dispositive power and voting power. Bermuda Holdco is a wholly owned subsidiary of Altria.

    (2)

    Based on a total of 382,011,178 Common Shares issued and outstanding as of March 31, 2024, based on information provided by the Issuer.


    CUSIP No. 22717L101

     

     1   

     NAME OF REPORTING PERSON

     

     Maple Acquireco (Canada) ULC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☒  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canada

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     - 0 -

        8   

     SHARED VOTING POWER

     

     156,573,537 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     - 0 -

       10   

     SHARED DISPOSITIVE POWER

     

     156,573,537 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     156,573,537 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     41.0% (2)

    14  

     TYPE OF REPORTING PERSON

     

     OO (unlimited limited company)

     

    (1)

    The amount reported represents 156,573,537 Common Shares directly and beneficially owned by Canada Acquireco with respect to which Canada Acquireco has shared dispositive power and voting power.

    (2)

    Based on a total of 382,011,178 Common Shares issued and outstanding as of March 31, 2024, based on information provided by the Issuer.


    This Amendment No. 2 is being filed by Altria Group, Inc. (“Altria”) to amend and supplement certain of the information set forth in the Schedule 13D originally filed by Altria on March 18, 2019, as amended by Amendment No. 1 filed by Altria on December 19, 2022 (as so amended, the “Original Schedule 13D” and as amended herein, the “Schedule 13D”), with respect to the common shares, no par value (the “Common Shares”), of Cronos Group Inc., a corporation incorporated under the laws of the Province of British Columbia, Canada (“Cronos” or the “Issuer”). Each Item below amends and supplements the information disclosed under the corresponding Item of the Original Schedule 13D. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Original Schedule 13D. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings herein as are ascribed to such terms in the Original Schedule 13D.

    ITEM 2. Identity and Background.

    Item 2 of the Original Schedule 13D is hereby amended and restated as follows:

    This Schedule 13D is being filed by Altria Group, Inc. (“Altria”), Altria Summit LLC (“Altria Summit”), Maple Holdco (Bermuda) Ltd. (“Bermuda Holdco”) and Maple Acquireco (Canada) ULC (“Canada Acquireco,” and, together with Altria, Altria Summit and Bermuda Holdco, the “Reporting Persons”).

    The business address of Altria and Altria Summit is 6601 West Broad Street, Richmond, Virginia 23230. The address of the registered office of Bermuda Holdco is Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of the registered office of Canada Acquireco is 1600—925 West Georgia Street, Vancouver, BC V6C 3L2 Canada. Altria is a holding company incorporated in the Commonwealth of Virginia in 1985. As of the date of Amendment No. 2 to the Schedule 13D, Altria’s wholly owned subsidiaries include, among others, Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co., which is engaged in the manufacture and sale of machine-made large cigars and is a wholly owned subsidiary of PM USA; UST LLC, which through its wholly owned subsidiary U.S. Smokeless Tobacco Company LLC, is engaged in the manufacture and sale of moist smokeless tobacco products and snus products; Helix Innovations LLC, which operates in the United States and Canada, and Helix Innovations GmbH and its affiliates, which operate internationally in the rest-of-world, are engaged in the manufacture and sale of oral nicotine pouches; and NJOY, LLC, which is engaged in the manufacture and sale of e-vapor products. Additional information regarding Altria’s business is available in Altria’s publicly filed reports with the Securities and Exchange Commission (the “SEC”).

    Altria Summit is a limited liability company organized under the laws of the Commonwealth of Virginia in 2013 and a wholly owned subsidiary of Altria. Its primary business is as an investment vehicle of Altria. Altria Summit is a manager-managed limited liability company and Altria is its sole member.

    Bermuda Holdco is a limited company organized under the laws of Bermuda in 2019 and a wholly owned subsidiary of Altria Summit. Its primary business is as an investment vehicle of Altria in connection with the Transaction (as defined in Item 6). As of the date of Amendment No. 2 to the Schedule 13D, Bermuda Holdco has not conducted any material activities other than those incidental to its formation and the matters contemplated in the Subscription Agreement (as defined in Item 6).

    Canada Acquireco is an unlimited liability company organized under the laws of British Columbia, Canada in 2019 and a wholly owned subsidiary of Bermuda Holdco. Its primary business is to invest from time to time in the securities of Cronos. As of the date of Amendment No. 2 to the Schedule 13D, Canada Acquireco has not conducted any material activities other than those incidental to its formation and the matters contemplated in the Subscription Agreement.

    Information required by Instruction C to Schedule 13D with respect to each executive officer and director of Altria, Bermuda Holdco and Canada Acquireco and each executive officer and manager of Altria Summit (collectively, the “Covered Persons”) is set forth on Annex A, attached and incorporated by reference.

    The Reporting Persons have not and, to the best knowledge of the Reporting Persons, none of the Covered Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    The Reporting Persons have not and, to the best knowledge of the Reporting Persons, none of the Covered Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


    ITEM 5. Interest in Securities of the Issuer.

    Item 5 of the Original Schedule 13D is hereby amended and restated as follows:

    Percentage interest calculations for Bermuda Holdco, Canada Acquireco, Altria and Altria Summit are based on a total of 382,011,178 Common Shares issued and outstanding as of March 31, 2024, based on information provided by the Issuer.

    The aggregate number of Common Shares that Canada Acquireco owns beneficially pursuant to Rule 13d-3 under the Act is 156,573,537 Common Shares, which constitutes approximately 41% of the Common Shares issued and outstanding as of March 31, 2024.

    As the sole shareholder of Canada Acquireco, Bermuda Holdco may be deemed the beneficial owner of the 156,573,537 Common Shares directly held by Canada Acquireco, which constitutes approximately 41% of the Common Shares issued and outstanding as of March 31, 2024.

    The aggregate number of Common Shares that Altria Summit owns beneficially pursuant to Rule 13d-3 under the Act is 156,573,537 Common Shares as of the date hereof, which constitutes approximately 41% of the Common Shares issued and outstanding as of March 31, 2024. This number includes 156,573,537 Common Shares directly held by Canada Acquireco, of which Altria Summit may be deemed the beneficial owner as the sole shareholder of Bermuda Holdco.

    The aggregate number of Common Shares that Altria owns beneficially pursuant to Rule 13d-3 under the Act is 156,573,537 Common Shares as of the date hereof, which constitutes approximately 41% of the Common Shares issued and outstanding as of March 31, 2024. This number includes 156,573,537 Common Shares directly held by Canada Acquireco, of which Altria may be deemed the beneficial owner as the sole member of Altria Summit.

    In addition, as of the date hereof, certain of the Covered Persons beneficially own the number and percentage of Common Shares set forth on Annex A attached and incorporated by reference.

    Additionally, pursuant to the IRA, Altria is entitled to customary pre-emptive and top-up rights to subscribe for additional Common Shares to maintain its ownership interest following issuances by Cronos in connection with certain triggering events, subject to a minimum ownership threshold and receipt of any necessary approvals.

    The Reporting Persons received the shared power to vote or to direct the vote and to dispose or to direct the disposition of 156,573,537 Common Shares.

    Except as described in this Schedule 13D, to the knowledge of the Reporting Persons, no transactions in the Common Shares were effected by the Reporting Persons or any Covered Person during the 60 days prior to the date of this Schedule 13D.

    To the knowledge of the Reporting Persons, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported in this Item 5.

    ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Original Schedule 13D is hereby amended as follows:


    The first paragraph in the subsection entitled “Investor Rights Agreement” is hereby amended by adding the following at the end of the last sentence thereof:

    On April 25, 2024, with respect to Altria’s designation of Murray R. Garnick for nomination for election to the Cronos Board at the 2024 annual meeting of Cronos shareholders (the “2024 Annual Meeting”), Cronos waived the requirement under Section 2.1(e) of the IRA that at least one Altria nominee must be “independent” under certain Canadian securities law standards, solely with respect to the 2024 Annual Meeting. The waiver is without prejudice to Altria’s views with respect to Mr. Garnick’s independence under those Canadian securities law standards.

    The following subsection entitled “Voting Agreement for the 2024 Annual Meeting,” is hereby added to Item 6 after the subsection entitled “Investor Rights Agreement” and before the section entitled “Other Commercial Agreements”:

    Voting Agreement for the 2024 Annual Meeting

    On April 25, 2024, Altria and the Issuer entered into a Voting Agreement (the “Voting Agreement”), pursuant to which Altria agreed, among other things, to vote all of the Common Shares beneficially owned by Altria (“Altria’s Common Shares”) at the 2024 Annual Meeting in favor of the proposals made by Cronos for the 2024 Annual Meeting, as more specifically set forth in, and subject to the terms and conditions of, the Voting Agreement (the “Proposals”). Pursuant to the terms of the Voting Agreement, Altria also agreed, at the 2024 Annual Meeting, to vote all of Altria’s Common Shares against any proposal inconsistent with any of the Proposals. With respect to the Proposal to appoint Cronos’s independent auditor for the year ended December 31, 2024, as more specifically set forth in the Voting Agreement, Cronos and Altria have agreed that Altria’s voting obligation is subject to, among other things, Cronos’s reasonable consultation with Altria with respect to the selection of such independent auditor and the unanimous approval of such selection by the Cronos board of directors.

    Altria may terminate the Voting Agreement upon the occurrence of certain events specified in the Voting Agreement, including, among other events, any failure to present the specified nominees for election at the 2024 Annual Meeting, any material breach of the Voting Agreement by Cronos or if Cronos’s new board of directors is not elected on or prior to June 20, 2024. The Voting Agreement will automatically terminate at the earliest to occur of (x) September 26, 2024 and (y) the filing of the Current Report on Form 8-K announcing the final voting results with respect to the Proposals.

    Incorporation by Reference; Joint Filing Agreement

    The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by reference to the Voting Agreement, a copy of which is attached as Exhibit 99.4 and is incorporated by reference. 

    In connection with the Transaction and the Schedule 13D, Altria and Altria Summit entered into a Joint Filing Agreement, which is attached as Exhibit 99.1 and incorporated by reference.

    ITEM 7. Material to be Filed as Exhibits.

    The following documents are filed as exhibits to this Amendment No. 2 to Schedule 13D:


    99.1    Joint Filing Agreement, dated as of March  18, 2019, between Altria Group, Inc., Altria Summit LLC, Maple Holdco (Bermuda) Ltd. and Maple Acquireco (Canada) ULC (incorporated by reference to Exhibit 99.1 to the Schedule 13D filed by Altria Group, Inc. on March 18, 2019 (File. No. 005-90505)).
    99.2    Subscription Agreement, dated as of December  7, 2018, by and among Cronos Group Inc., Altria Summit LLC and, solely for the purposes set forth therein, Altria Group, Inc. (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Altria Group, Inc. on December 7, 2018 (File. No. 001-08940)).
    99.3    Investor Rights Agreement, dated as of March  8, 2019, by and among Cronos Group Inc. and Altria Group, Inc. (incorporated by reference to Exhibit 99.3 to the Schedule 13D filed by Altria Group, Inc. on March 18, 2019 (File. No. 005-90505)).
    99.4    Voting Agreement, dated as of April  25, 2024, by and among Cronos Group Inc. and Altria Group, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Cronos Group Inc. on April 25, 2024).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: April 25, 2024     ALTRIA GROUP, INC.
        By:  

    /s/ Heather A. Newman

        Name:   Heather A. Newman
        Title:   Senior Vice President, Chief Strategy and Growth Officer
    Date: April 25, 2024     ALTRIA SUMMIT LLC
        By:  

    /s/ Steven S. Schroder

        Name:   Steven S. Schroder
        Title:   Manager, Vice President and Treasurer
    Date: April 25, 2024     MAPLE HOLDCO (BERMUDA) LTD.
        By:  

    /s/ Steven S. Schroder

        Name:   Steven S. Schroder
        Title:   Director and President
    Date: April 25, 2024     MAPLE ACQUIRECO (CANADA) ULC
        By:  

    /s/ Steven S. Schroder

        Name:   Steven S. Schroder
        Title:   Director and President


    Annex A

    The following table sets forth the name and present occupation or employment of each director and executive officer of Altria Group, Inc. Maple Holdco (Bermuda) Ltd. and Maple Acquireco (Canada) ULC and each executive officer of Altria Summit LLC. With the exception of Ian L.T. Clarke, each such person is a citizen of the United States. Mr. Clarke is a citizen of Canada. The business address of each such person is 6601 West Broad Street, Richmond, Virginia 23230.

    Directors of Altria Group, Inc.:

     

    Name   

    Present Occupation or Employment

    Ian L.T. Clarke    Retired Chief Financial Officer, Greater Toronto Airports Authority
    Marjorie M. Connelly    Retired Chief Operating Officer, Convergys Corporation
    R. Matt Davis   

    President, Driftwood Leadership, LLC

    Retired President, North America, and Senior Vice President, Global Corporate Affairs, Dow Inc.

    William F. Gifford, Jr.    Chief Executive Officer, Altria Group, Inc.
    Debra J. Kelly-Ennis    Retired President and Chief Executive Officer, Diageo Canada, Inc.
    Kathryn B. McQuade    Retired Executive Vice President and Chief Financial Officer, Canadian Pacific Railway Limited
    George Muñoz   

    Principal, Muñoz Investment Banking Group, LLC

    Partner, Tobin & Muñoz

    Nabil Y. Sakkab1   

    Retired Senior Vice President, Corporate Research and Development,

    The Procter & Gamble Company

    Virginia E. Shanks    Retired Executive Vice President and Chief Administrative Officer, Pinnacle Entertainment, Inc.
    Ellen R. Strahlman    Retired Executive Vice President, Research & Development and Chief Medical Officer, Becton, Dickinson and Company
    M. Max Yzaguirre    Retired Executive Chairman, Forbes Bros. Holdings, Ltd.

     

    1

    Dr. Sakkab beneficially owns 5,000 Common Shares, which represents less than 1% of the Common Shares issued and outstanding as of March 31, 2024, based on information provided by the Issuer.


    Executive Officers of Altria Group, Inc.:

     

    Name   

    Present Occupation or Employment

    Jody L. Begley    Executive Vice President and Chief Operating Officer
    Daniel J. Bryant    Vice President and Treasurer
    Steven D’Ambrosia    Vice President and Controller
    William F. Gifford, Jr.    Chief Executive Officer
    Salvatore Mancuso    Executive Vice President and Chief Financial Officer
    Bob McCarter    Executive Vice President and General Counsel
    Heather Newman    Senior Vice President, Chief Strategy and Growth Officer
    W. Hildebrandt Surgner, Jr.    Vice President, Corporate Secretary and Associate General Counsel
    Charles N. Whitaker    Senior Vice President, Chief Human Resources Officer and Chief Compliance Officer

    Directors of Maple Holdco (Bermuda) Ltd.:

     

    Name   

    Position at Reporting
    Person

      

    Present Occupation or Employment

    Steven S. Schroder    President    Managing Director and General Manager International, Altria Ventures Inc.

    Executive Officers of Maple Holdco (Bermuda) Ltd.:

     

    Name   

    Position at Reporting
    Person

      

    Present Occupation or Employment

    Steven S. Schroder    President    Managing Director and General Manager International, Altria Ventures Inc.

    Directors of Maple Acquireco (Canada) ULC:

     

    Name   

    Position at Reporting
    Person

      

    Present Occupation or Employment

    Steven S. Schroder    Director    Managing Director and General Manager International, Altria Ventures Inc.

    Executive Officers of Maple Acquireco (Canada) ULC:

     

    Name   

    Position at Reporting
    Person

      

    Present Occupation or Employment

    Steven S. Schroder    President    Managing Director and General Manager International, Altria Ventures Inc.
    Mary C. Bigelow    Secretary    Sr. Assistant General Counsel, Altria Client Services LLC


    Managers of Altria Summit LLC:

     

    Name   

    Position at Reporting
    Person

      

    Present Occupation or Employment

    Steven S. Schroder    Manager    Managing Director and General Manager International, Altria Ventures Inc.
    Mary C. Bigelow    Manager    Sr. Assistant General Counsel, Altria Client Services LLC

    Executive Officers of Altria Summit LLC:

     

    Name   

    Position at Reporting
    Person

      

    Present Occupation or Employment

    Steven S. Schroder    Vice President and Treasurer    Managing Director and General Manager International, Altria Ventures Inc.
    Mary C. Bigelow    Vice President and Secretary    Sr. Assistant General Counsel, Altria Client Services LLC
    Get the next $CRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    1/27/2022$5.54 → $3.24Underperform → Hold
    Jefferies
    More analyst ratings

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Doucet Terrence Gregory Joseph converted options into 12,876 shares and covered exercise/tax liability with 6,266 shares, increasing direct ownership by 10% to 70,141 units (SEC Form 4)

      4 - Cronos Group Inc. (0001656472) (Issuer)

      5/13/25 6:36:28 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Weigensberg Arye converted options into 12,132 shares, increasing direct ownership by 10% to 129,469 units (SEC Form 4)

      4 - Cronos Group Inc. (0001656472) (Issuer)

      5/13/25 6:35:37 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Officer Buggy Shannon

      4 - Cronos Group Inc. (0001656472) (Issuer)

      5/13/25 6:34:30 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Cronos Appoints Anna Shlimak as Chief Financial Officer

      TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

      3/19/25 7:30:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

      TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g

      7/22/24 4:15:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders

      TORONTO, June 21, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held yesterday, June 20, 2024 (the "Meeting"), shareholders holding a total of 274,097,252 common shares of the Company voted in person or by proxy, representing 71.75% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 26, 2024 was elected as a director of the Company, with each director receiving in excess of 93.4% of the votes cast in favor of his or her election. The detailed results of the vote for the electio

      6/21/24 4:30:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cronos Group Inc.

      10-Q - Cronos Group Inc. (0001656472) (Filer)

      5/8/25 7:33:20 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Cronos Group Inc. (0001656472) (Filer)

      5/8/25 7:32:08 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Cronos Group Inc.

      DEFA14A - Cronos Group Inc. (0001656472) (Filer)

      4/25/25 4:35:16 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Financials

    Live finance-specific insights

    See more
    • Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

      TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

      4/24/25 8:00:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025

      TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

      2/24/25 4:45:45 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

      TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

      10/29/24 4:15:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cronos Group Inc. to Hold Virtual 2025 Annual Meeting of Shareholders

      TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 Annual Meeting of Shareholders on Friday, June 20, 2025, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2025 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote. The Company's proxy statement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting is avail

      4/28/25 4:00:00 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

      TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

      4/24/25 8:00:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Unveils New Spinach® 1.2g Vapes and SOURZ by Spinach® Gummies Enhanced with Rare Cannabinoids

      TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc.'s (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") best-selling cannabis brand, Spinach®, is thrilled to introduce three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach® Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio.Peach Passionfruit Kush CBN (Indica): A dreamy, restful expe

      4/22/25 8:00:00 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

      SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

      4/25/24 6:39:55 PM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

      SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

      12/19/22 8:47:03 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Cronos Group with a new price target

      Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

      11/2/22 6:32:18 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Cronos Group from Hold to Buy

      7/28/22 9:01:16 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group upgraded by CIBC

      CIBC upgraded Cronos Group from Neutral to Sector Outperform

      5/11/22 7:33:42 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care